Your browser doesn't support javascript.
loading
Non-permissive SARS-CoV-2 infection in human neurospheres.
Pedrosa, Carolina da S G; Goto-Silva, Livia; Temerozo, Jairo R; Souza, Leticia R Q; Vitória, Gabriela; Ornelas, Isis M; Karmirian, Karina; Mendes, Mayara A; Gomes, Ismael C; Sacramento, Carolina Q; Fintelman-Rodrigues, Natalia; Soares, Vinicius Cardoso; Dias, Suelen da Silva Gomes; Salerno, José Alexandre; Puig-Pijuan, Teresa; Oliveira, Julia T; Aragão, Luiz G H S; Torquato, Thayana C Q; Veríssimo, Carla; Biagi, Diogo; Cruvinel, Estela M; Dariolli, Rafael; Furtado, Daniel R; Borges, Helena L; Bozza, Patrícia T; Rehen, Stevens; Souza, Thiago Moreno L; Guimarães, Marília Zaluar P.
Afiliação
  • Pedrosa CDSG; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Goto-Silva L; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Temerozo JR; National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Souza LRQ; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Vitória G; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Ornelas IM; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Karmirian K; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Mendes MA; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Gomes IC; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Sacramento CQ; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Fintelman-Rodrigues N; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Soares VC; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Dias SDSG; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Salerno JA; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Puig-Pijuan T; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Oliveira JT; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Aragão LGHS; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Torquato TCQ; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Veríssimo C; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Biagi D; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Cruvinel EM; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Dariolli R; Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Furtado DR; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Borges HL; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Bozza PT; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Rehen S; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Souza TML; Pluricell Biotech, São Paulo, SP, Brazil.
  • Guimarães MZP; Pluricell Biotech, São Paulo, SP, Brazil.
bioRxiv ; 2021 Jun 17.
Article em En | MEDLINE | ID: mdl-33052345
Coronavirus disease 2019 (COVID-19) was initially described as a viral infection of the respiratory tract. It is now known, however, that several other organs are affected, including the brain. Neurological manifestations such as stroke, encephalitis, and psychiatric conditions have been reported in COVID-19 patients, but the neurotropic potential of the virus is still debated. Herein, we sought to investigate SARS-CoV-2 infection in human neural cells. We demonstrated that SARS-CoV-2 infection of neural tissue is non-permissive, however, it can elicit inflammatory response and cell damage. These findings add to the hypothesis that most of the neural damage caused by SARS-CoV-2 infection is due to a systemic inflammation leading to indirect harmful effects on the central nervous system despite the absence of local viral replication.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos